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Currently, the best way to reduce the mortality of cancer is to detect and treat it in the earliest stages. Technological advances in
genomics and proteomics have opened a new realm of methods for early detection that show potential to overcome the drawbacks of
current strategies. In particular, pattern analysis of mass spectra of blood samples has attracted attention as an approach to early
detection of cancer. Mass spectrometry provides rapid and precise measurements of the sizes and relative abundances of the proteins
present in a complex biological/chemical mixture. This article presents a review of the development of clinical decision support sys-
tems using mass spectrometry from a machine learning perspective. The literature is reviewed in an explicit machine learning frame-
work, the components of which are preprocessing, feature extraction, feature selection, classiﬁer training, and evaluation.
 2005 Elsevier Inc. All rights reserved.
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Cancer is a major public health concern in the US. In
2004, there will be more than 1.3 million new cancer
cases and more than 563,000 deaths due to cancer
[1,2]. Cancer accounts for one of every four deaths in
the US [2]. Currently, the best way of reducing the mor-
tality of cancer is to detect and treat it in the earliest
stages [3]. For example, when breast cancer is detected
at the advanced stage, in which cancer is metastasized
from the original organ to others, the survival rate is
only 23%. However, when breast cancer is detected at
the early stage, in which cancer is localized in organ of
origin, the survival rate increases to 97% [2]. Similarly,
the survival rate of prostate cancer soars from 34% when1532-0464/$ - see front matter  2005 Elsevier Inc. All rights reserved.
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100% at the early stage [2].
A cancer screening test is considered eﬃcacious if it
results in a decrease in cause-speciﬁc mortality. Neces-
sary evidence in favor of a particular screening test in-
cludes earlier detection of disease than would have
occurred due to presentation of symptoms and evidence
that earlier treatment will result in a better outcome.
(There is a helpful overview online at http://cancer.
gov/cancertopics/pdq/screening/overview.) Screening and
diagnostic tests are typically evaluated in terms of their
sensitivity and speciﬁcity. Sensitivity is the fraction of
disease cases that are correctly identiﬁed as disease.
Speciﬁcity is the fraction of non-disease cases that are
correctly identiﬁed as non-disease.
Currently, there exist eﬀective screening tests for use
in the general population for only a few types of cancer.
The screening methods that are best supported by the
evidence to date are (1) the Pap smear for cervical cancer
screening, (2) mammography for breast cancer detec-
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cancer screening. While there are limitations to each of
these methods, there is evidence that they have made
substantial contributions to reducing the morbidity
and mortality due to cancer.
A Pap smear is an exfoliative cytological staining pro-
cedure that can help identify premalignant and malig-
nant changes in the cervical epithelium. The incidence
of, and mortality of women due to, cervical cancer has
declined about 70% in the US since the Pap was intro-
duced in the 1950s. Use of this screening test reduces
the incidence as well as mortality since the Pap smear
can detect precancerous changes that can be treated.
However, with a speciﬁcity of only 63%, many false-po-
sitive Pap smears occur in screening the general popula-
tion, in which cervical cancers and precancerous lesions
are thankfully rare [4]. Unfortunately, false negative Pap
smears also occur since the sensitivity of the exam is 73%
[4].
Mammography, X-ray imaging of the breasts, is used
to detect breast cancer. Mammography has reduced the
mortality of breast cancer by approximately 25–30% in
the US since the 1970s [5,6]. Mammography also suﬀers
from false positives due to the combination of moderate
speciﬁcity and low disease prevalence. Only 15–34% of
the positive cases from mammography are found to be
actually malignant at biopsy [7,8]. False negatives also
occur since the sensitivity of mammography is approxi-
mately 90% [9].
Fecal occult blood testing (FOBT) is used for the
early detection of colorectal cancer. It can detect colo-
rectal cancer by measuring blood loss in the stool, which
mainly occurs due to colorectal neoplasms [10,11].
FOBT is reported to have reduced the mortality of colo-
rectal cancer in the US by 33% [12,13,10,11]. FOBT has
a fairly high speciﬁcity of 96–98% [12]. However, be-
cause the sensitivity of the FOBT is merely 40% [12],
there is concern that the diagnosis and treatment of
colorectal cancer can be delayed due to false negative
tests.
An ideal cancer screening method would be accurate,
non-invasive, and inexpensive. As discussed above, the
accuracy levels of existing screening methods are far
from ideal. The false negatives resulting from screening
methods in current use delay the diagnosis of cancer,
which can lead to increased morbidity and mortality.
The false positives generated by the early detection
methods used in current practice necessitate additional
diagnostic testing which increases costs, discomfort,
and stress. Existing screening modalities are all invasive
to some extent: a Pap smear is obtained from a pelvic
exam, mammography is based on exposure to ionizing
radiation and compression of the breasts, and FOBT re-
quires a stool sample. Many variables are believed to im-
pact compliance with existing screening programs, but
physical discomfort and embarrassment are probablyimportant factors (e.g., [14]). The costs associated with
current approaches to cancer screening remain problem-
atic as well (e.g., [15]).
Recent technological advances in genomics and pro-
teomics have opened a new realm of early detection,
showing potential to overcome the drawbacks of current
early detection strategies. A biomarker is a biologically
derived molecule in the body that indicates the progress
or status of a disease. The concentration level or pattern
of biomarkers related to a certain type of cancer can be
used for early detection or diagnosis. Studies of the
application of biomarkers for early cancer detection
can be summarized into two categories: the usage of a
single biomarker and the pattern analysis of multiple
biomarkers.
When a single biomarker is used, the concentration le-
vel of the biomarker is taken as an indicator of the pres-
ence or absence of cancer. A threshold is set on the
concentration level of a biomarker and if the concentra-
tion level is higher than the threshold, the specimen is
considered ‘‘positive’’ for cancer. An example of early
detection based on a single biomarker is the use of pros-
tate-speciﬁc antigen (PSA) in blood to detect prostate
cancer. PSA is a protein secreted by the epithelial cells
of the prostate gland. The PSA level in blood is generally
low in healthy people or patients with benign prostate dis-
ease such as benign prostatic hyperplasia (BPH), but it
tends to rise in many patients with malignancies [16].
However, the speciﬁcity of using the concentration level
of PSA as an indicator of prostate cancer ranges from
only 18 to 50% with a sensitivity of 70–90% [16]. The
low speciﬁcity causes many false positives to occur; there-
fore, unnecessary biopsies are performed to corroborate
the absence of prostate cancer. There is considerable de-
bate as to whether screening for prostate cancer by PSA is
eﬃcacious [3,17–20].
The problems encountered with the PSA biomarker
suggest limitations that may plague any test based on
a single biomarker. Given the high level of biological
variability and the fact that cancer cells are derived from
normal cells in the body, it may not be possible to iden-
tify a single circulating protein that can identify the pres-
ence of cancer with high sensitivity and speciﬁcity in the
general population. Even for high-risk populations (e.g.,
CA 125 for women at high risk for ovarian cancer [21]),
it is unlikely that single biomarkers will provide as accu-
rate testing as the use of multiple biomarkers.
An important diﬃculty in developing tests based on
single biomarkers is that the identiﬁcation process de-
mands a vast amount of time and labor [20]. Tradition-
ally, 2D gel electrophoresis (2DE) has been used for
biomarker identiﬁcation in tandem with mass spectrom-
etry [22,23,19,24,20]. A protein expressed diﬀerently be-
tween cancer and normal specimens is extracted using
2DE and the extracted protein is identiﬁed by peptide
ﬁngerprinting using mass spectrometry and protein/
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because it is extremely time-consuming and laborious
[25,26,20].
Recently, pattern analysis of multiple biomarkers in
blood samples has attracted attention as an alternative
to the usage of a single biomarker for early detection
of cancer. The pattern diﬀerences of protein proﬁles be-
tween cancer and healthy samples are perceived using
data mining algorithms. Multiple proteins rather than
a single protein are used as a panel of biomarkers in
this approach. Because these pattern diﬀerences origi-
nate from the complexity of blood, which is a mixture
of thousands of proteins, a protein proﬁling modality
with high-throughput and high sensitivity is required.
Mass spectrometry has the potential to meet these
requirements by providing the sizes and relative abun-
dances of the proteins in a complex biological/chemical
mixture in a rapid and precise manner [27–31]. Recently,
studies have been performed on a several types of
cancer, including ovarian [32–43], prostate [44–50,40,
51–53], breast [54,55], bladder [56,57], lung [58–72], liver
[73], pancreatic [74–79], renal cell carcinoma [80], colo-
rectal [81], and astroglial tumor [82]. Most of these stud-
ies reported fairly high sensitivities and speciﬁcities (over
80%). However, many questions have been raised about
the reliability of these reported results due to the ‘‘black
box’’ methods employed [83–86,53,87].
Diamandis [85] pointed out that the peak height does
not linearly correspond to the protein abundance be-
cause mass spectrometry only provides the relative
abundance of proteins in a sample. He also inquired
about why diﬀerent data mining algorithms had pro-
duced diﬀerent sets of potential biomarkers. He took
as an example the studies on prostate cancer performed
by Qu et al. [49] and Petricoin et al. [88]. They achieved
high sensitivities (96%: Qu et al.; 95%: Petricoin et al.)
and speciﬁcities (98%: Qu et al.; 83%: Petricoin et al.)
with diﬀerent sets of potential biomarkers selected
through diﬀerent data mining algorithms. Another ques-
tion is why known biomarkers, for example PSA, do not
seem to be reﬂected by the studies so far and the poten-
tial biomarkers found in these studies have fairly low
mass [84–86]. Since low mass proteins are easily cleared
by the kidney, the eﬃcacy of a panel of low mass pro-
teins appears to be suspicious. Related to this, Diaman-
dis and Merwe [87] also raised another question on
whether or not the putative biomarkers identiﬁed
through the ‘‘black box’’ methods originate from can-
cer-speciﬁc pathological states in the body. They took
an example Koomen et al.s [75] study on the identiﬁca-
tion of potential biomarkers for pancreatic cancer. Koo-
men et al. [75] identiﬁed several biomarker candidates
for pancreatic cancer from mass spectra of human plas-
ma of healthy people and pancreatic cancer patients
using statistical and biochemical tests. However,
Diamandis and Merwe argued that these biomarkercandidates can be only high abundance non-cancer-spe-
ciﬁc proteins in blood, which are produced by non-spe-
ciﬁc epiphenomena of cancer presence. Moreover, they
suspected that the current mass spectrometers such as
MALDI-TOF or SELDI-TOF are not sensitive enough
to detect low abundance clinically useful biomolecules
without an aid of powerful fractionation [87].
In addition to Diamandis questions, Baggerly et al.
[83,89] emphasized the problems in quality control indi-
cated by the lack of reproducibility of the studies of Pet-
ricoin et al. [88] and Zhu et al. [43]. In these both studies,
the ovarian cancer data sets posted on the website of the
clinical proteomics program under the national cancer
institute (http://home.ccr.cancer.gov/ncifdaproteomics/)
were analyzed to identify diagnostic signatures for ovar-
ian cancer. Baggerly et al. attempted to reproduce the
experimental results obtained by Petricoin et al. by fol-
lowing the proposed bioinformatic algorithms as much
as possible; however, Baggerly et al.s [83] analyses imply
that the apparent successes of the study may have been
due to artifacts of sample processing rather than actual
biological pattern diﬀerences. In the analyses on Zhu et
al.s study, Baggerly et al. [89] also showed that the
peaks identiﬁed as potential biomarkers in one data
set may not have consistently occurred in another set
measured on a diﬀerent date from the ﬁrst set. Similarly,
Yasui et al. [53] discussed the variability of the relative
abundance of the same protein across chips and sam-
ples, which also points to the need for active and system-
atic internal quality controls.
Recently, some progress has been made in addressing
these important questions. For example, low mass bio-
markers may be more meaningful than many had be-
lieved because other high abundance and high mass
proteins such as albumin can act as carriers of low mass
biomarkers. These carrier proteins enable low mass bio-
markers to stay in the body longer than expected [90].
Powerful fractionation techniques amplify the concen-
tration of these low mass biomarkers by isolating them
from the carrier proteins such that mass spectrometers
can suﬃciently detect the pathological signatures of
these low mass biomarkers [17,90].
In addition, in response to Baggerly et al. [89], Liotta
et al. pointed out that those two ovarian data sets used in
Zhu et al.s study were measured under diﬀerent experi-
mental settings (e.g., chemistries on protein chips, pH, la-
ser energy intensity, etc.) as well as on diﬀerent days;
thus, simple comparisons of two diﬀerent mass spectral
data reproducibility may lead to a hasty generalization
[91]. Similarly, Grizzle et al. [92] also maintained that it
would be very unlikely for diﬀerent laboratories to derive
similar sets of biomarker candidates when applying dif-
ferent bioinformatics algorithms to samples obtained
from non-identical patient populations.
Such issues related to reproducibility can be resolved
to some extent if strongly standardized calibration and
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ries. Recently, Semmes et al. [93] reported that ‘‘be-
tween-laboratory’’ reproducibility of SELDI-TOF MS
can reach ‘‘within-laboratory’’ reproducibility levels if
calibration and instrumentation protocols are strongly
standardized among diﬀerent laboratories. Six diﬀerent
institutions succeeded in classifying prostate cancer sam-
pled from healthy samples using a classiﬁer trained in an
institution within an acceptable variance of error rates
after calibrating the SELDI-TOF MS machines with
the standard pooled serum samples distributed by one
of these institutions. This study was performed as a part
of an on-going eﬀort to validate the approach of cancer
detection through serum protein expression proﬁling
using SELDI-TOF MS [94].
However, many questions remain unanswered. In
Semmeset al.s study, while mass accuracy of the healthy
samples used for the quality control agreed within an
acceptable variance, their peak intensities, especially
small peak intensities, showed fairly high variation de-
spite of careful calibration. Moreover, for classiﬁcation,
Semmes et al. selected prostate cancer and healthy sam-
ples that had been used in building the classiﬁer in their
previous study and on which the classiﬁer performed
well. Thus, as Semmes et al. discuss in their article, their
study only shows the possibility that the experimental
platform can be reproducible under very rigorous uni-
ﬁed calibration and instrumentation protocols and more
work is needed on this important issue.
For reliable early detection based on pattern analysis
of multiple biomarkers, more rigorous and systemic ap-
proaches are needed. In this article, we review the liter-
ature on the development of clinical decision support
systems using mass spectrometry in an organized frame-
work from a machine learning perspective. Study design
and quality control (e.g., sample preparation and mass
spectrometer parameter settings) are also extremely
important issues because data quality, which is mostly
determined by these processes, aﬀects the overall perfor-
mance of decision support systems. However, since these
issues are beyond the scope of this article, we will refer
the reader to other papers that have discussed the topic
of study design and quality control for experiments
based on protein proﬁling techniques [95–98,93].2. Mass spectrometry
Mass spectrometry provides rapid and precise mea-
surements of the sizes and relative abundances of the
proteins present in a complex biological/chemical mix-
ture. Here we provide a very brief overview of the tech-
nique as it is typically used for identifying cancer
biomarkers from blood samples. We refer the reader
to other articles for a thorough review of mass spec-
trometry methods [99–104].The capabilities of a mass spectrometer are deter-
mined by its ion source, mass analyzer, and detector.
Protein proﬁling of plasma and serum has been per-
formed primarily with a matrix-assisted laser desorption
ionization (MALDI) ion source or its derivative, the sur-
face-enhanced laser desorption ionization (SELDI) ion
source coupled to a time-of-ﬂight (TOF) mass analyzer
with a chevron microchannel plate detector. The only
diﬀerence between SELDI and MALDI is the use of
derivatized surfaces to capture peptides and proteins
based on particular physical or biochemical characteris-
tics prior to MALDI sample preparation and mass anal-
ysis. A brief description of MALDI-TOF mass analysis
is given in the following paragraphs.
To prepare proteins or peptides for MALDI mass
analysis, aqueous solutions of the proteins or peptides
are mixed with solutions of matrix molecules, like sina-
pinic acid and a-cyano-4-hydroxycinnamic acid, which
are present in large molar excess compared to the pro-
teins and peptides (10,000:1). Aliquots of this mixture
are deposited on the MALDI plate and allowed to dry
(this procedure is referred to as the dried droplet tech-
nique). The peptides and proteins selectively cocrystal-
lize with the MALDI matrix as the solvent evaporates.
After drying, the sample plate is introduced into the vac-
uum chamber of the mass spectrometer and placed in
the MALDI ion source. To produce ions, an ultraviolet
laser (337 or 355 nm) is used to irradiate the matrix crys-
tals. The energy from these photons is transferred into
translational and vibrational energy causing desorption
of matrix material containing the peptide and protein
analytes. The softer process ionization of MALDI
(when compared to laser desorption ionization) prevents
fragmentation of the protein and peptide analytes [103].
However, ionized clusters of matrix molecules produce
chemical noise, which interferes with the ion signals of
interest: those corresponding to the peptides and pro-
teins [105,106].
After a delay of a few hundred nanoseconds (Wiley–
McLaren time lag focusing), all ions are extracted from
the source and accelerated into the TOF mass analyzer.
The voltage settings in the ion source determine the
range of optimized ion signal; i.e., the TOF has mass-de-
pendent focusing. The ions drift in a ﬁeld free region,
where they are separated based on their mass-to-charge
ratios. The principle behind this separation is that the
potential energy of each ion in an electric ﬁeld
(U = zV) is converted into the kinetic energy of the
ion in the TOF ðE ¼ 1
2
mv2Þ. By setting these equations
equal to one another, the TOF equation can be derived
and rearranged to calculate m/z value for an ion:
zV ¼ 1
2
mv2; ð1Þ
v ¼ l
t
; ð2Þ
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¼ m
z
. ð3Þ
In Eq. (1), z denotes the ions charge amount, V is the
electric potential that accelerates the ion, m is the ions
mass, and v is the ions velocity. In Eq. (2), l is the length
of the ﬂight tube of the TOF mass spectrometer and t
the ﬂight time of the ion. Eq. (3) shows that the mass-
to-charge ratio can be represented as a quadratic func-
tion of the ﬂight time. Ions of the same m/z have the
same ﬂight time and thus impact the detector at the
same time. When the ion strikes the detector, a cascade
of secondary electrons is released. This current is cap-
tured by an anode and converted to a voltage using a
preampliﬁer. The resulting voltage is recorded by a dig-
ital storage oscilloscope or by a digitizer card in a com-
puter, and the amplitude of the signal corresponds to the
number of ions that struck the detector in each bin of
ion ﬂight time. Other sources of noise from physical
and electrical components of the mass spectrometer
are also recorded (e.g., high frequency noise).
Data are recorded as plots of intensity versus ﬂight
time and displayed as intensity versus m/z: referred to
as a mass spectrum (Fig. 1). In each mass spectrum,
the individual ion signals correspond to non-volatile
analytes in the original sample. In protein proﬁling,
these ion signals primarily correspond to peptides and
proteins because of the analyte speciﬁcity of the matrices
described above. The mass-to-charge ratios (m/z), dis-
played as the x-axis, can be used to calculate the molec-
ular weights of protein or peptide in the proﬁle. For the
analysis of complex mixtures, like plasma or serum pro-
tein fractions, MALDI-TOF MS has detection sensitiv-
ity in the 0.1–10 pmol range and mass measurement
accuracy ranging from 0.01 to 0.5%. Ion signals in diﬀer-
ent mass spectra with centroids m/z values within the
mass measurement error tolerance should be considered
to be the same peak (protein). Because of the complexity
of the samples, which produces suppression eﬀects, and
the lack of internal and external standards for quantiﬁ-
cation, the intensity of the ion signals in the protein pro-
ﬁles does not directly correlated to protein
concentration [90]. Nonetheless, relative abundances of
a particular ion signal can be determined by comparingFig. 1. Example of a mass spectrum in which the relative abundance is
monotonically decreasing baseline. A portion of the spectrum has been enlamass spectra acquired from diﬀerent samples. Thus,
noise reduction and normalization schemes are critical
to enable accurate statistical analysis of mass spectra.
Ciphergen (Freemont, CA) developed a SELDI-TOF
system to accomplish both fractionation and mass anal-
ysis in a succinct and accurate manner. SELDI-TOF is a
special case of MALDI-TOF in which chromatography
is performed using protein chips that can capture only
those proteins that biochemically/chemically match cer-
tain binding characteristics (e.g., hydrophobic), even
when a variety of proteins are mixed together in high
concentrations [107–109,31,110,111]. The selected ‘‘frac-
tion’’ of proteins deposited on the protein chip is ana-
lyzed through MALDI-TOF mass spectrometry.
SELDI-TOF enables to amplify the mass abundance
information on more proteins than other types of mass
spectrometry using the protein chip with the predeﬁned
chromatographic surface [90].
Recently, more advanced types of mass spectrome-
tery have been tested to improve the sensitivity to diag-
nostic patterns in protein proﬁling [33,35,48,51].
Whereas the traditional mass spectrometers provide
15,000–40,000 m/z data records, high-resolution mass
spectrometers can extend these to 350,000–400,000
[35]. The hybrid quadrupole time-of-ﬂight (QqTOF)
such as QSTAR pulsar I (Applied Biosystems, Framing-
ham, MA, USA) is a frequently used model for this pur-
pose. To the best of our knowledge, there have been no
studies in which types high-resolution mass spectrome-
ters were extensively compared and discussed. One ex-
pects that the development of more eﬃcient and
eﬀective preprocessing and feature extraction/selection
algorithms will be even more important issues for
high-resolution MS than in traditional MALDI-TOF
or SELDI-TOF because of the increase in size of each
of data record.3. Blood samples
This article reviews approaches that are being ex-
plored for cancer diagnosis using mass spectrometry of
blood samples. There are several advantages to usingplotted as a function of the mass-to-charge ratio (m/z). Notice the
rged so that the high frequency noise is apparent.
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more invasive than some diagnostic imaging modalities,
there is relatively little discomfort and low risk of side
eﬀects or adverse events associated with blood testing.
Obtaining blood samples is less expensive than many
other procedures. The primary disadvantage of using
blood samples is that one expects that tumors located
in most organs of the body will produce few proteins
that will circulate in the blood at an appreciable level.
Throughout our discussion, we refer generically to
‘‘blood samples’’; however, the reader should note that
mass spectrometry is not performed on whole blood
but on derived products, particularly plasma or serum.
Plasma is the liquid portion of blood in which the cells
are suspended; serum is the ﬂuid that remains after clot-
ting proteins are removed from plasma [112]. The
advantage of using plasma rather than serum is that it
contains more proteins and that the protease activity,
which leads to protein degradation, is inhibited in plas-
ma but not in serum. However, the disadvantage of
using plasma is that low abundance proteins associated
with disease may be diﬃcult to detect in the presence of
a large amounts of common proteins involved in clot-
ting. Both plasma and serum have been used in studies
of cancer diagnosis using mass spectrometry and it is
not yet known which is best for this kind of analysis.
There have been many studies of the serum/plasma
proteomes using techniques such as 2D gel electrophore-
sis (e.g. [113]). However, to the best of our knowledge,
for the most part this information has not been
incorporated into studies of cancer diagnosis using mass
spectrometry. It is possible that more accurate models
for sample classiﬁcation could be developed if prior
knowledge of blood proteins could be properly taken
into account.4. Framework for system development
We employ a machine learning framework to review
the literature on the development of clinical decision
support systems utilizing mass spectrometry of blood
samples. There are ﬁve stages of data analysis in this
framework. First, the spectra are preprocessed to reduce
the contribution of noise and to normalize the spectra
from diﬀerent samples such that they are comparable.
Second, features reﬂecting the pathological status of a
sample are extracted from the mass spectra. Interpret-
able features, such as peaks corresponding to distinct
protein species, are generally preferred. Third, highly
discriminant features are selected to reduce the dimen-
sionality of the data, which increases the likelihood of
successful classiﬁcation. Fourth, machine learning mod-
els are designed to distinguish cancer from normal sam-
ples based on the selected features. Fifth, the system is
evaluated in terms of clinically relevant metrics such assensitivity and speciﬁcity. Ideally, separate data sets
should be used for each stage. However, in practice
some form of data partitioning of a single data set, such
as cross-validation or bootstrap sampling, is employed
due to the diﬃculties of obtaining a large number of
spectra. The ﬁve stages are mutually dependent and
the best combination of methods to be used at each
stage must be determined empirically.
4.1. Preprocessing
Biomedical data are notoriously complex and vari-
able. The goal of preprocessing methods is to ‘‘clean
up’’ the data such that machine learning algorithms will
be able to tease out key information and correctly clas-
sify new samples based on a limited set of examples. In
analyzing mass spectra of blood samples, the prepro-
cessing stage includes two main tasks: noise reduction
and normalization.
In mass spectrometry, the noise is the undesired inter-
fering signal caused by sources unrelated to the bio-
chemical nature of the sample being analyzed and the
signal is the relative abundance of ions originating from
the proteins in the sample. Many studies to date have
not employed explicit noise reduction schemes other
than basic noise reduction methods implemented on
commercial mass spectrometers (e.g., the SELDI-TOF
mass spectrometer from Ciphergen, Freemont, CA).
However, some investigators have explored methods
for reducing noise, particularly the baseline and high fre-
quency noise [58,96,114,61,62,64,115,69,43,116].
Mass spectra exhibit a monotonically decreasing
baseline (Fig. 1). As described above, it is necessary to
add a matrix material to the sample of interest. How-
ever, it is possible for the matrix material to interact
with itself as well as with the sample proteins. The base-
line originates from small clusters of matrix material.
Because the chances of cluster formation decrease with
cluster size, the baseline diminishes monotonically as
the mass-to-charge ratio increases [105,102]. The mono-
tonically decreasing baseline can be regarded as low fre-
quency noise because the baseline lies over a fairly long
mass-to-charge ratio range [117]. Most studies that have
employed a baseline reduction method have taken a
two-step approach: baseline estimation followed by sub-
traction of the estimated baseline from the original mass
spectrum.
A variety of approaches have been explored to esti-
mate the baseline from mass spectra. Such approaches
can be summarized into two major categories: heuristic
or model-based. Heuristic approaches form non-para-
metric estimates of the baseline from a set of mass spec-
tra. Model-based approaches build a mathematical
model of the baseline based on the physics of the mass
spectrometer and estimate the parameters of the model
from a set of mass spectra. The baseline estimated by
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spectrum. So far, there have been many more studies
using heuristic approaches [58,96,75,62,64,69] than
model-based approaches [116].
There have been several studies in which a heuristic
approach was used to estimate and eliminate the base-
line. A local average or minimum intensity within a
moving window has been used as a local estimator of
the baseline and the overall baseline is estimated by slid-
ing the window over the mass spectrum [58]. Piecewise
linear regression has been applied to the regions with a
monotonically decreasing baseline [64,69]. The baseline
has also been estimated by calculating the convex hull
of the intensities of the proteins in a region [62]. All
these algorithms seem to eﬀectively estimate the underly-
ing baseline, at least in some circumstances. However,
the parameters of these algorithms, e.g., the width of
the window in a piecewise linear regression model, have
been determined in an ad hoc manner. For methods in
which a sliding window or piecewise linear regression
are employed for baseline elimination, the window size
is a critical factor determining the overall performance.
If the window size is too large, these methods may over-
simplify the curvature of the baseline with a long
straight line. If the window size is too small, they may
produces an overly complex estimate of the baseline,
which is very sensitive to high frequency noise.
There are no absolute standards for deciding which
one among the heuristic baseline estimation algorithms
is more eﬀective than the others; each algorithm has its
strengths and weaknesses. For example, choosing the
minimum peak intensity within the sliding window as a
local baseline estimator is superior to piecewise linear
regression in terms of computation time. However, the
latter method is expected to be relatively less sensitive
to high frequency noise than the former one because a
straight line with the minimum sum of errors between
the line and peak intensities within the windows is calcu-
lated as a local estimator by linear regression. The con-
vex hull is deﬁned as the minimal convex set of given
objects [118]. Thus, the convex hull of a mass spectrum
is the piecewise straight lines connecting the local minima
on the spectrum. This can be easily visualized by imagin-
ing a rubber band tightly stretched to encompassing the
lower side of the mass spectrum. Since the convex hull is
calculated based on the local minima, it may also suﬀer
from the interference from high frequency noise.
To the best of our knowledge, there has only been
one model-based approach reported in the literature to
date [116]. Malyarenko et al. [116] used a model for
the baseline in SELDI-TOF was developed using the
phenomenon of charge accumulation that decays expo-
nentially on the ion detector. Greater emphasis will
likely be placed on model-based approaches in the fu-
ture because they may be more eﬀective with limited
data sets since a priori knowledge is taken into account.Mass spectra of blood samples also exhibit an addi-
tive high frequency noise component (Fig. 1). The pres-
ence of this noise hampers both data mining algorithms
and human observers in ﬁnding meaningful patterns in
mass spectra. While several prior studies have explored
methods for reducing the inﬂuence of this high fre-
quency noise [114,61,62,116,115,119,43], few have at-
tempted to identify or describe the sources of this
noise or to determine proper models for its statistical
characteristics [120,96,105,106,117]. Moreover, to date,
no study has used such noise characterization work to
develop a ‘‘model-based’’ high frequency noise reduc-
tion scheme.
The heuristic high frequency noise reduction ap-
proaches employed most commonly in studies to date
are smoothing ﬁlters [62,119,43], the wavelet transform
(WT) [114,50,71], or the deconvolution ﬁlter [116]. Typ-
ical smoothing ﬁlters are the Gaussian ﬁlter [119,43] and
moving average ﬁlter [62]. These smoothing ﬁlters smear
out the high frequency noise signal in the spectra by
averaging the intensities within a moving window. In
the case of a Gaussian ﬁlter, the intensities are weighted
by a Gaussian kernel before calculating the average.
Over the past decade, the WT has been frequently used
for chemical/biological signal processing [121,122]. The
WT is a type of signal decomposition algorithm that al-
lows us to view a signal as a superposition of weighted
basis functions with diﬀerent frequencies and time shifts.
The frequency range and time location of the high fre-
quency noise are localized using the WT. Then the high
frequency noise can be eﬀectively reduced by manipulat-
ing the weight coeﬃcients of the basis functions
[121,114,61,50,122]. The deconvolution ﬁlter reduces
noise by minimizing the sum of squared errors between
the desired output and ﬁltered signal and the power of
ﬁltered noise. In this case, it is assumed that the ob-
served signal can be modeled as the sum of the true sig-
nal and additive stationary noise [123]. Malyarenko et
al. [116] applied the deconvolution ﬁlter to SELDI-
TOF mass spectra and reported that it reduced noise
and improved the resolution.
All of the methods have made considerable contribu-
tions to high frequency noise reduction in mass spectra.
However, since no study has extensively compared the
methods introduced above on the same data set, it is
diﬃcult to conclude if one method is better than the
others. Moreover, the overall performance of those high
frequency noise reduction methods is highly dependent
on the choice of the ﬁlter parameters (e.g., the size of
the sliding window or the kernel weights) and the true
eﬀectiveness of those methods is diﬃcult to measure
due to the lack of knowledge on the statistical character-
istics of the signal and noise in mass spectra.
Most noise reduction approaches to date have
emphasized designing ﬁlters based on empirical insight
rather than rigorous statistical noise analysis. However,
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mass spectrometry and to measure the statistical charac-
teristics of the noise [120,96,105,106,117]. Such studies
are critical because the lack of information on the statis-
tical characteristics of the true signal and the noise may
lead to the design of ﬁlters that remove the desired signal
or fail to remove the noise. In other words, aggressive
ﬁltering may smear out diagnostically informative pat-
terns and insuﬃcient ﬁltering may leave high levels of
noise in the signal. Because low abundance proteins
are expected to contain diagnostically useful informa-
tion, noise reduction approaches that ignore statistical
noise analysis may actually make it more diﬃcult to de-
tect diﬀerences in the spectral patterns between cancer
and healthy samples. In future work, these noise charac-
terization studies could provide the basis for model-
based approaches to noise reduction.
A peak in mass spectra indicates the relative abun-
dance of a protein; therefore, the magnitudes of mass
spectra cannot be directly compared with each other.
Normalization methods scale the intensities of mass
spectra to make mass spectra comparable (Fig. 2). The
most frequently used normalization method is normali-
zation with respect to the total ion current (TIC), i.e.,
the sum of all the peaks in a mass spectrum [58,54,74,
77,36,124,46,55,125,65,56]. Normalization with respect
to the mean spectrum has also been used, which isFig. 2. Normalization is need to compare across spectra since mass
spectrometry provides a measure of the relative abundance of the
diﬀerent proteins in a sample. In the illustration here, the original
spectra (A) are normalized such that the maximum peak heights in
each spectra are the same (B).equivalent to normalization with respect to TIC [43].
Other studies have performed normalization with re-
spect to the largest peak [60,69] or linear scaling using
the largest and smallest peak intensities [33,63,39,41].
Normalization with respect to one or two peaks within
a spectrum may be more sensitive to noise than normal-
ization with respect to TIC because the eﬀect of noise at
those peaks is transferred to all other peaks through
normalization while noise will be canceled out by the
summation of peak intensities in normalization with re-
spect to TIC.
The four normalization methods described above are
performed within a spectrum. Normalization across
samples has also been investigated. All the peak intensi-
ties at the same mass-to-charge ratio across samples can
be normalized with respect to the median peak intensity
[73,67] or linearly scaled using the largest and smallest
peak intensities [35,125]. Some investigators have ex-
tended simple linear scaling by taking the peak variabil-
ity into consideration [115]. These methods ignore the
absolute diﬀerence in peak intensities at diﬀerent mass-
to-charge ratios and consider only the diﬀerence in the
expression levels between cancer and normal samples.
Therefore, small peaks can be considered to be as impor-
tant as large peaks in normalization across samples.
However, it should be noted that noise embedded in
small peaks can also be ampliﬁed by such normalization
methods and it still remains unanswered whether peaks
belonging to diﬀerent spectra can be manipulated with-
out any precedent normalization within a spectrum. At
present, it is not clear if one normalization method is
superior to the others since there have not been any
studies in which normalization methods were compared
on the same data set.
Some studies have investigated the use of the log
transform to reduce the variability of mass spectra
[77,124,46,55,65,115,66,42]. However, one should be
cautious in using the log transform since it may make
it diﬃcult to separate the additive noise component from
the original signal. Suppose that mass spectra have addi-
tive random noise with zero mean. Such noise can easily
be reduced by simple averaging; however, such noise
cannot be reduced by simple averaging after a log trans-
form because summation in the log space corresponds to
multiplication in the original space. In addition to the
log transform, the square root transform has also been
investigated as a means of reducing the variability [65].
4.2. Feature extraction
Features are variables constructed from preprocessed
data to summarize the properties of the data [126,127]
and the process of constructing features is called as ‘‘fea-
ture extraction.’’ In decision support systems utilizing
mass spectra, feature extraction can be deﬁned as a pro-
cess of extracting summary information reﬂecting the
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spectra.
The simplest approach to feature extraction from
mass spectra is to use the abundance (intensity) informa-
tion of every m/z measured as the features [59,37–39,
41–43]. While this approach to feature extraction is
straightforward, it places additional demand on the fea-
ture selection and classiﬁcation stages since a very large
number of features are used (15,000) and most studies
employ a modest number of cases (<500). Moreover,
mass spectrometers can only distinguish the masses of
proteins within a ﬁnite resolution level. More than one
m/zmeasured can correspond to the same protein. Thus,
high levels of correlation are expected between close m/z
values.
Some studies have employed binning to extract fea-
tures from the raw mass spectra [58,33,63,48,51]. The
m/z points are grouped into a number of bins and a fea-
ture is derived from each bin by calculating the average
[63] or the maximum peak intensity [58]. The spacing of
bins is usually uneven because the number of peaks is
not uniformly distributed [63]. Binning is the simplest
form of peak detection and alignment, which will be dis-
cussed in depth from the next paragraph, in a sense that
bins are deﬁned over the m/z axis but they are initially
placed at ﬁxed positions across multiple spectra and
never adjusted again. Binning is also fairly straightfor-
ward to use; however, care must be taken in determining
the size and location of bins because improper binning
may lead to producing incorrect features, which do
not enough reﬂect the pathological status of samples.
Since abundance data from within the mass error rate
are considered to represent the same protein, features
are often extracted from mass spectra based on the
properties of ‘‘peaks’’ that are comprised of multiple
m/z points. In this approach, feature extraction consists
of three main components: peak detection, peak align-
ment, and calculation of feature metrics. Often, com-
mercial software provided with mass spectrometers
(e.g., Ciphergens SELDI-TOF system) and in-house
algorithms are combined in the feature extraction
process.
The identiﬁcation of peaks in a mass spectrum is
complicated by the error in measuring the abundance
as well as the mass error rate. The goal of peak detection
is to identify sets of m/z values which comprise ‘‘peaks’’
that are higher than the noise level of a mass spectrum.
In many studies, commercial software has been used to
ﬁnd as many peaks as possible and a predeﬁned thresh-
old has been applied to select peaks far higher than the
noise level. For example, Ciphergen ProteinChip soft-
ware detects peaks based on the signal-to-noise ratio
(S/N). The S/N is an indicator of how much a peak is
distinguished from background noise. If the S/N of a
peak is 10, the peak has an intensity value 10 times lar-
ger than background noise. Ciphergen ProteinChip soft-ware ﬁrst selects peaks with a high signal to noise ratio
(e.g., S/NP 10) within individual mass spectra. Then,
across mass spectra, it ﬁnds more peaks with a moder-
ately high S/N (e.g., S/NP 2) [114,128]. Some research-
ers have explored alternative peak detection algorithms
for more rigorous peak ﬁnding [96,124,62,66,53]. Most
peak detection algorithms ﬁnd local maxima within a
certain mass-to-charge ratio range and choose the local
maxima higher than a threshold of the noise level as
peaks [96,124,69,53]. Local maxima of a mass spectrum
are located by ﬁnding the mass-to-charge ratios with the
highest intensity among their N neighbors [96,53].
Clearly, peak detection algorithms must include a
deﬁnition of the noise level around a local maximum.
The noise level is often deﬁned as the average of the
intensities at the mass-to-charge ratios within a moving
window with a ﬁxed size (e.g., 5% of all mass-to-charge
ratios in a mass spectrum) [53] or as the median elevated
level from the median diﬀerence of all local maxima and
their adjacent local minima in a mass spectrum [96].
Peak detection, as described above, is concerned with
identifying peaks within a single mass spectrum. How-
ever, to make inferences about trends across several
spectra, one must relate the peaks identiﬁed in one spec-
trum to the peaks identiﬁed in another spectrum. This
process of matching peaks that represent the same pro-
tein specie across multiple spectra is referred to as ‘‘peak
alignment’’ (Fig. 3). In peak alignment, the peaks of
multiple mass spectra within the mass error rate are
grouped together and regarded as a ‘‘peak group.’’
Most peak alignment algorithms group the peaks
around a prominent peak within a moving window the
size of the mass error rate in a mass spectrum. Then,
the peak groups within the mass error rate are re-
grouped across spectra and the members of a group
are adjusted [44,74,77,36,124,46,67,69,52,119]. In one
study, a genetic algorithm was employed to optimize
the process of window-based peak alignment [70]. Peak
alignment simply based on the mass error rate can pro-
duce peak groups that cannot eﬀectively represent pro-
teins in a complex sample. A genetic algorithm was
used to identify the peaks that were present across the
most samples while at the same time avoid those that
were within the mass error rate of those already selected.
After peak detection and peak alignment, one must
deﬁne the metrics of a peak group that will serve as fea-
tures. Feature metrics related to peak heights have been
used in most studies. The maximum peak height [64,39],
average peak height [74,63], and median peak height of a
peak group [68] have been used. Instead of retaining the
peak height as continuous feature data, binary [53] and
discretized feature [60] values have also been investi-
gated as a way to alleviate the variability of feature val-
ues across samples that can deteriorate the
generalization of the classiﬁer. Binary feature values
indicate whether a peak is expressed over the noise level
Fig. 3. The left panel illustrates peak detection, which is concerned with identifying peaks within a single mass spectrum. The right panel illustrates the
process of matching peaks that represent the same protein species across multiple spectra (A and B), which is referred to as ‘‘peak alignment.’’
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to which a peak is expressed. Some studies have em-
ployed the sum of peaks in a peak group, i.e., the ion
current of a peak group, to take into account the contri-
butions of all the peaks representing one protein [35,64].
Most feature extraction methods, as described above,
extract features from signals in the original space, i.e.,
peak intensities of mass spectra. In a few studies, fea-
tures were extracted by projecting the signals from the
original space onto another, usually lower-dimensional,
space through linear transformations. Principal compo-
nent analysis (PCA) has been widely used as a standard
way for this purpose in many other data mining applica-
tions [129]. PCA identiﬁes the orthogonal directions in
which data vary maximally using the eigenvalue/eigen-
vector decomposition of the covariance matrix. Then
the original signals are projected onto those directions,
the number of which is usually smaller than the original
dimension. The projections are called principal compo-
nents and often used as features. Since only those direc-
tions that explain data variation maximally are selected
in PCA, the projected data is of a lower dimension, but
with a minimum loss of information. In one study, every
m/z point was regarded as a dimension and PCA was
applied to ﬁnd principal components, which were used
as features in clustering analysis [61]. The WT has been
also employed not only to reduce noise but also to ex-
tract features from mass spectra in a similar fashion as
PCA is used [50,71]. The WT also compresses data by
projecting the original data onto prespeciﬁed orthogonal
directions (wavelets). The coeﬃcient of each wavelet be-
comes a feature in this case [50,71]. Since the wavelets
representing high frequency components are usually ig-
nored, noise reduction is simultaneous accomplished
with feature extraction. Both approaches are very sensi-
tive to the choice of components (i.e., principal eigenvec-
tors in PCA or wavelets in the WT); therefore, it isimportant to determine criteria for selecting eigenvec-
tors or wavelets prior to feature extraction. However,
this is currently performed in an ad hoc manner. In
addition, as compared with methods that select features
in the original space, the features resulting from PCA or
the WT are less interpretable because the features are ex-
tracted from the projected space. Thus, the inverse trans-
formations are needed to reveal how features (m/z
points) in the original space contribute to creating each
feature in the projected space.
In feature extraction, a variety of peak detection and
alignment algorithms are being developed and tested.
The resolution and noise of mass spectrometry systems
should be taken into account. For example, using the
maximum peak of a peak group might lead to over/un-
derestimation of relative abundance of a certain protein
because it can be easily aﬀected by noise. Likewise, peak
alignment that only considers the mass error rate might
deteriorate the sensitivity and speciﬁcity. It is possible
that better diagnostic systems could be developed if
more prior knowledge of mass spectrometry and the
proteins present in blood was incorporated into the fea-
ture extraction process.
4.3. Feature selection
The purpose of feature extraction is to produce a set
of quantitative measures from a mass spectrum that
could potentially be used for distinguishing spectra of
normal and cancer samples. Typically, the feature
extraction process results in a smaller set of features
(<1000) than the number of (m/z, relative abundance)
pairs that were in the original spectrum (15,000). How-
ever, in general, the number of features extracted is still
much larger than the number of samples (<500) in an
experiment. This imbalance in the number of features
and samples may increase the chances of misclassiﬁ-
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redundant features [130,131,127,132,40]. Also, a large
number of features usually lead to an increase in the
training time of classiﬁers. Moreover, from a biomedical
perspective, it is important to ﬁnd a moderate number of
proteins that most contribute to correct classiﬁcation
such that these potential biomarkers can be identiﬁed
and biochemically validated. Thus, it can be important
to reduce the number of features from the set initially
extracted. This process is referred to as feature selection.
Feature selection is deﬁned as a series of actions to
choose a subset of features that are relevant to correct
classiﬁcation based on speciﬁed evaluation and selection
criteria [131,127,132,38]. Feature selection methods are
often categorized as ﬁlters, wrappers, or embedded meth-
ods (Fig. 4). A ﬁlter method evaluates and ranks individ-
ual features based on selection criteria (e.g., t statistic).
Then, a subset of features for classiﬁcation is determined
based on individual feature ranks. Wrappers assess the
relevancy of a subset of features based on evaluation
metrics of a classiﬁer trained using that subset of fea-Fig. 4. Feature selection methods are often categorized as ﬁlters (top
panel), wrappers (middle panel), or embedded methods (bottom
panel). A ﬁlter method evaluates and ranks individual features based
on selection criteria (e.g., t statistic). Then, a subset of features for
classiﬁcation is determined based on individual feature ranks. Wrap-
pers assess the relevancy of a subset of features based on evaluation
metrics of a classiﬁer trained using that subset of features. Embedded
methods implicitly perform feature selection as a part of the classiﬁer
training process (e.g., decision tree).tures. A search algorithm is used to explore the space
of feature subsets and identify a high-performing subset
of features. Cross-validation or bootstrap sampling are
used in conjunction with wrapper methods since they
can provide the unbiased accuracy estimates of the clas-
siﬁer. Embedded methods implicitly perform feature
selection as a part of the classiﬁer training process.
Filters have been the most commonly used type of
feature selection in prior studies of cancer classiﬁcation
using mass spectra. A variety of statistical tests have
been investigated to deﬁne selection criteria for the rele-
vancy of individual features. The two-sample t test has
been used in many studies [59,75,76,36,73,133,43]. A t
test for two independent samples (cancer, normal) is per-
formed on each feature across the training samples and
features that show a statistically signiﬁcant diﬀerence
(e.g., p < 0.05) in the group means are selected for use
in training classiﬁers. Other studies have also used meth-
ods related to the t test for two independent samples. Li
et al. [38] deﬁne the distance between two sample
groups, cancer and normal, as the absolute mean diﬀer-
ence normalized by the root mean square of the vari-
ances of two sample groups. This distance measure
resembles the two-sample t test for independent samples
with unequal variance. Zhu et al. [43] calculated a
reliable threshold for p value based on 1D Gaussian ran-
dom ﬁeld considering the fact that multiple comparisons
are made. Other types of statistical tests such as the
v2 test [79,133], the one-way analysis of variance (ANO-
VA) [69,52], the Wilcoxon signed rank test [74,45,41,72],
and the Mann–Whitney test [72] have also been used to
rank features.
Some studies have tested the eﬃcacy of relevancy
measures on the basis of information theory and signal
processing as ﬁlters. Information gain and relief-F
[132,134] are examples of measures used in information
theory based ﬁlters [60]. The wavelet transform can also
be used as a ﬁlter method for feature selection. In one
study, features were assessed by comparing the wavelet
coeﬃcients of each feature between cancer and normal
samples [71]. Receiver operating characteristics (ROC)
analysis [135] has also been used to measure the rele-
vancy of an individual feature. The area under the curve
of each feature is calculated and it is used as the metric
to rank features [44]. ROC analysis is discussed further
in the evaluation section.
Using a single relevancy measure can lead to biased
feature selection. Thus, combinations of methods have
been investigated for feature selection [74,36,70]. A fea-
ture is considered to be relevant when the feature re-
ceives high scores from multiple methods. This
approach enables one to explore features from diﬀerent
perspectives and to make a more reliable decision
regarding the selected subset of features.
Wrappers are diﬀerent from ﬁlters in that classiﬁer
evaluation metrics are used rather than selection criteria
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groups rather than individually. Filters employ selection
criteria such as statistical tests to evaluate individual fea-
tures, while wrappers use evaluation metrics of classiﬁ-
ers to estimate the discriminating power of a candidate
subset of features [130,131,127,132]. Moreover, while ﬁl-
ters simply select a subset of features by choosing those
that were highly ranked individually, wrappers itera-
tively optimize the subset selection using search algo-
rithms such as genetic algorithms and stepwise
selection methods [130,131,127,132]. The wrapper ap-
proach typically has better performance than the ﬁlter
approach since the search process in wrappers enables
it to exclude redundant features when forming a subset
of features [127,132]. However, the ﬁlter approach does
have the advantage that is less computationally demand-
ing than the wrapper approach [132,38].
Several studies have investigated the eﬃcacy of wrap-
pers for feature selection in mass spectra. The combina-
tion of genetic algorithms [134] with classiﬁers is a
popular use of wrappers in this ﬁeld [58,38,39]. Several
kinds of classiﬁers have been combined with genetic
algorithms, including self-organizing maps [33,34,48,
39], support vector machines (SVM) [38], and simple
distance based classiﬁers (e.g., Mahalanobis distance)
[58,75,50]. In other studies, stepwise feature selection
methods (forward selection and backward elimination)
[127] have been used instead [64,41]. A wrapper that
incorporates uniﬁed maximum separability analysis
(UMSA) and bootstrap sampling has identiﬁed the
best performing subset of features in three studies
[77,46,55].
Embedded methods implicitly perform feature selec-
tion as a part of the classiﬁer training process [127].
For example, decision trees estimate the contribution
of individual features to correct classiﬁcation in each
iteration and grow the tree structure according to the
estimation result. Therefore, when the training is over,
the ﬁnal subset of features is produced with the classiﬁer
[127,134]. Feature selection using embedded methods
for mass spectra will be further discussed in the next sec-
tion on classiﬁcation.
Feature selection can help to reduce running time and
avoid overtraining if it succeeds in ﬁnding a subset of
independent and discriminating features. Unfortunately,
there is no guarantee that the feature selection process
will improve the classiﬁcation performance. Moreover,
features selected as relevant for classiﬁcation still need
to be biologically validated in future studies. Eﬀorts to
identify the proteins corresponding to relevant features
should follow feature selection and classiﬁcation studies.
4.4. Classiﬁer training
Machine learning is a branch of artiﬁcial intelligence
that is concerned with design and application of algo-rithms that enable computers to learn from experience
[134]. We interpret this deﬁnition broadly to include
techniques that were developed from a statistical, rather
than computer science perspective, such as linear dis-
criminant analysis and regression.
There are three general types of machine learning
algorithms: unsupervised, reinforcement, and super-
vised. In unsupervised learning, the computer attempts
to identify natural groupings within a dataset based on
criteria that deﬁne how ‘‘similar’’ items are and what
makes a ‘‘good’’ group, but without being provided
examples of the feature values of items and associated
‘‘correct’’ class membership. For this reason, unsuper-
vised learning methods are also referred to as ‘‘cluster-
ing.’’ Unsupervised learning algorithms have not been
used in many prior studies of cancer diagnosis from
mass spectra. Some studies have explored self-organiz-
ing maps [33,34,48,39,51] and hierarchical clustering
algorithms [124,73,65] in this ﬁeld. In reinforcement
learning, the computer is not provided with examples
of the feature values of items and associated ‘‘correct’’
class membership, but is provided less speciﬁc feedback
that indicates if the system is on the right track. We are
unaware of any studies of mass spectra for cancer diag-
nosis that employ reinforcement learning methods. In
supervised learning, the computer is provided with
examples of the feature values of items and associated
‘‘correct’’ class membership. The goal of supervised
learning is to develop a ‘‘classiﬁer’’ that can predict
the class membership from a set of pre-determined clas-
ses for an item based on a set of features that describe
the item. Supervised learning methods have been used
extensively in the investigation of cancer diagnosis from
mass spectra. Prior studies have tested the performance
of several supervised learning algorithms including arti-
ﬁcial neural networks (ANN) [82,60,73,125,68,136],
k nearest neighbor (KNN) [60,125,69,52,43], logistic
regression [77,36,46,55,64], decision trees [44,54,60,63,
64,125,80,71], linear or quadratic discriminant analysis
(LDA/QDA) [58,47,64,50,66,69,52,42], support vector
machines (SVMs) [38,125,69,42], kernel matching pur-
suit (KMP) [62], logical analysis of data (LAD) [32],
stepwise discriminant analysis [41], partial least square
projection [61,65], Naı¨ve Bayes [60], rule induction
[60], and ensemble algorithms (e.g., boosting, bagging,
or random forest) combined with various base classiﬁers
[37,49,42,53]. Two evolving themes in the use of super-
vised learning in this ﬁeld are the emphases on SVMs
and ensemble methods.
SVM is a fairly new class of supervised machine
learning methods that has generated considerable excite-
ment (Fig. 5). SVMs are a type of kernel learning meth-
ods, which project data from the current vector space to
another vector space where linear learning algorithms
can be applicable. The functions that project the data
onto the new vector space, which usually has a higher
Fig. 5. SVMs are a type of kernel learning methods, which project
data from the current vector space to another vector space where linear
learning algorithms can be applicable. SVMs guarantee the maximal
margin between cancer and normal samples through global optimiza-
tion of the decision boundary such that overtraining can easily be
avoided (margin indicated by arrow). Since the decision boundary set
by SVMs has the gradient that allows for the maximum-margin
separation based on a few data samples closest to the decision
boundary, which are called support vectors (highlighted with gray),
SVMs implicitly reﬂect the contribution of each feature to successful
classiﬁcation and reduce the eﬀect of irrelevant features by performing
the dot product between the gradient and each sample.
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tions. Since an improper kernel function may worsen
classiﬁcation by projecting data onto a space where lin-
ear separation is impossible, care must be taken for
choosing a kernel function when using SVMs. Unfortu-
nately, there are no guidelines for choosing the best ker-
nel for a given data set. Prior knowledge of the
characteristics of data may help with this process, but
in practice selecting an optimal kernel remains a signif-
icant challenge. The most popularly used kernel func-
tions are the polynomial, radial basis function, and
sigmoid kernels.
After data projection into a linear space, SVMs guar-
antee the maximal margin between cancer and normal
samples through global optimization of the decision
boundary such that overtraining can easily be avoided
[137,138]. In the cases where the projected data is still
not linearly separable, for example, when two classes
overlap, a penalty is given to the objective function of
optimization to trade the margin size and misclassiﬁ-
cation rate. A small penalty maximizes the margin size
but increases the misclassiﬁcation rate while a large
one decreases the margin size but minimizes the mis-
classiﬁcation rate [139].SVMs can also be utilized without any data projec-
tion if the data are linearly separable in the current vec-
tor space. This method is usually called linear-SVMs.
Since the decision boundary set by SVMs has the gradi-
ent that allows for the maximum–margin separation
based on a few data samples closest to the decision
boundary, which are called support vectors, SVMs
implicitly reﬂect the contribution of each feature to suc-
cessful classiﬁcation and reduce the eﬀect of irrelevant
features by performing the dot product between the gra-
dient and each sample. There is less need for an eﬀective
feature selection step when a classiﬁer that is robust to
irrelevant features is used. The robustness of SVMs to
irrelevant and redundant features is especially valuable
since mass spectra data sets typically have many more
features than cases. Thus, SVMs exhibit several proper-
ties that are appealing in the analysis of mass spectra.
The complexity and subtlety of mass spectra patterns
between cancer and normal samples may increase the
chances ofmisclassiﬁcation when a single classiﬁer is used
because a single classiﬁer tends to cover patterns originat-
ing from only part of the sample space. Therefore, it
would be beneﬁcial if multiple classiﬁers could be trained
in such a way that each of the classiﬁers covers a diﬀerent
part of the sample space and their classiﬁcation results
were integrated to produce the ﬁnal classiﬁcation.
Ensemble algorithms such as bagging, boosting, or
random forests improve the classiﬁcation performance
by associating multiple base classiﬁers to work as a
‘‘committee’’ for decision-making [140,141]. Any super-
vised learning algorithm can be used as a base classiﬁer.
Ensemble algorithms not only increase the classiﬁcation
accuracy, but also reduce the chances of overtraining
since the committee avoids a biased decision by integrat-
ing the diﬀerent predictions from the individual base
classiﬁers.
Feature selection has been performed as an ‘‘embed-
ded’’ part of the training process in many studies, espe-
cially when decision tree or SVM methods were used.
Decision trees select the most discriminant features
based on the information gain at each stage when grow-
ing the tree structure. As a result, a list of features that
make the largest contributions to successful classiﬁca-
tion are obtained when classiﬁer training is ﬁnished. In
some studies of cancer classiﬁcation using mass spectra,
features selected implicitly by decision trees have been
proposed as potential biomarkers [44,49,80]. SVMs also
possess embedded feature selection mechanisms. As de-
scribed in the earlier part of this section, the decision
boundary includes the information of each features rel-
evancy for successful classiﬁcation. For example, in the
case of the linear SVM, the absolute magnitude of coef-
ﬁcients of the decision boundary (a hyperplane) corre-
sponds to the degree of relevancy of features. Prados
et al. [125] proposed a list of potential biomarkers using
the internal feature selection function of a linear SVM.
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sify unknown samples within a reasonably bounded er-
ror range. While the error of a classiﬁer on the
training set decreases as the training process proceeds,
the error on the general population increases after a cer-
tain time point in the training process because the clas-
siﬁer becomes oversensitive to the patterns that exist
only in the training set. This event is called as ‘‘over-
training.’’ It is important to avoid overtraining by eval-
uating the classiﬁer performance using an independent
set of samples. In addition, it is impossible to ﬁnd a clas-
siﬁcation algorithm superior to the others for all feature
selection methods because every classiﬁcation algorithm
has its own learning bias [126,134]. The performance of
a classiﬁcation algorithm can be varied by the choice of
feature selection methods. For example, KNN is very
sensitive to irrelevant and redundant features. However,
in prior studies, the relationship between the chosen fea-
ture selection method and classiﬁcation algorithm has
not been thoroughly researched. It is necessary to iden-
tify the best pair of a feature selection method and
classiﬁer.
4.5. Evaluation
After a system is developed through the stages de-
scribed in the previous sections, its performance must
be carefully assessed. In this section we discuss two
important issues in system evaluation. First, the quality
of the data set used to develop the system will strongly
inﬂuence its performance since systems for cancer diag-
nosis from mass spectra are inherently data-driven. Sec-
ond, the system evaluation must be based on criteria
that are clinically relevant and quantitative with clearly
deﬁned standards of interpretation.
The desired characteristics of the data are that they
provide an accurate representation of the population
to be tested and that there are suﬃcient data to allow
for robust inference. There are many factors that can
bias a sample such that it does not correctly describe
the population, e.g., the choice of human subject inclu-
sion/exclusion criteria, data entry errors, etc. This prob-
lem is complicated by the fact that disease cases typically
must be present in the data set at a much higher propor-
tion than the population prevalence in order to show the
breadth of variability in the disease state with a limited
overall sample size. The imbalance in the sizes of disease
and healthy classes can make classiﬁers more sensitive to
patterns originating from disease cases, resulting in
more false positives in classiﬁcation. If there are more
healthy cases, the number of false negatives will increase
because patterns from healthy cases will be relatively
more emphasized. From this point of view, it is valuable
to equalize the class sizes [142–144]. However, there
would be diﬃculty in keeping the balance between dis-
ease and healthy sample sets as one attempts to increasethe entire sample size for more robust and reliable infer-
ence because disease cases are usually more diﬃcult to
obtain than healthy ones. To the best of our knowledge,
this issue has not yet been addressed in the arena of ana-
lyzing mass spectra. Over-sampling the minority class
and under-sampling the majority class have been com-
mon methods to resolve biased classiﬁcation due to
imbalanced data. The basic idea behind these techniques
is to balance the sizes of two classes artiﬁcially. For
example, over-sampling the minority class, i.e., sampling
with replacement, increases the size of the minority class
up to that of the majority class. Similarly, under-sam-
pling the majority class, i.e., decimating samples, can re-
duce the size of the majority class up to that of the
minority class. However, it should be noted that these
two techniques must be carefully used because over-
sampling a minority class may lead to overtraining to
a speciﬁc pattern of the samples belonging to the minor-
ity class and under-sampling a majority class may lose
some valuable patterns of majority class samples
[142,144]. Some studies have tried to resolve this issue
by penalizing the error rates of the samples of the minor-
ity class more, which prevents the classiﬁer from sacriﬁc-
ing those samples of the minority class to decrease the
overall error rates (e.g., 1-accuracy) [142–144].
Proper handling of mislabeled data samples is also an
important issue for classiﬁer training and evaluation.
There are two approaches to contending with mislabeled
data. One is to reduce the likelihood of its existence
through experimental design and quality control. The
second is to eliminate mislabeled data in post hoc fash-
ion during the analysis. In practice, since even extremely
rigorous experimental design and quality control may
not be able to perfectly prevent the occurrence of misla-
beled data, both approaches should be taken to alleviate
the eﬀects of mislabeled data on decision support sys-
tems [145–147].
To avoid mislabeled data through experimental de-
sign and quality control, we must consider the possible
sources. For example, mislabeling can arise from data
entry errors. To a large extent, this can be avoided
through rigorous laboratory protocols. A more concern-
ing source of mislabeled data is genuine confusion
regarding the correct classiﬁcation of a sample due to
the error or limitations inherent to the diagnostic test
used to establish truth or the absence of a test for truth.
For example, a healthy sample may be mislabeled as po-
sitive based on a false-positive biopsy. This type of error
can be avoided if samples are only included for study if
they have undergone conﬁrmatory testing (e.g., repeated
biopsy). On the other hand, a diseased sample can be
mislabeled as healthy either because of a false-negative
diagnostic test or because no diagnostic testing was per-
formed (e.g., an asymptomatic subject was presumed to
be healthy). Given the limitations of existing diagnostic
tests for detecting very early stage disease and the many
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healthy individuals, this can be an important source of
false-negative samples. The most common approach to
avoid this problem is to only consider a healthy sample
to be healthy after an appropriate duration of disease-
free follow-up time [148]. To the best of our knowledge,
this issue has not been explicitly discussed in any reports
of studies of cancer classiﬁcation from mass spectrome-
try to date. Moreover, we are unaware of any studies
that have demonstrated and analyzed the risk of system
performance degradation due to mislabeled training/test
data samples in the context of mass spectrometry
analysis.
The machine learning literature can provide some
guidance on post hoc methods for detecting mislabeled
samples. Mislabeled samples may appear as outliers.
Therefore, detecting mislabeled samples is closely re-
lated to detecting outliers. Some approaches for outlier
detection have been developed. For example, simply
analyzing the means and standard deviations of features
with the conﬁdence intervals of each feature can reveal
outliers [145] because samples lying outside the conﬁ-
dence interval are highly probable to be outliers. Clus-
tering algorithms also can be used to identify outliers
[149,145]. Presumably, samples belonging to the same
class would be clustered together while outliers would
behave as ones belonging to other classes. Note that this
clustering should be performed prior to feature selec-
tion. Other studies have used multiple classiﬁers of dif-
ferent types to ﬁlter out outliers [150,151]. The key
idea is that the samples whose labels were consistent
with the labels predicted by multiple classiﬁers were
regarded as correct samples and that were not were
regarded as outliers.
There is no theory to provide ﬁrm guidance on the
sample sizes required to properly perform any of the
stages of development of clinical decision support sys-
tems utilizing mass spectrometry of blood products.
Sometimes, it is easy to identify in retrospect that a sam-
ple may have been too small, such as when an algorithm
fails to converge or operates with unacceptably low per-
formance. However, one needs to take care in devising
evaluation strategies that help avoid the common and
diﬃcult problem of the system appearing to perform
well on the data set used for development but proving
unsatisfactory when subjected to additional testing with
more data. Fortunately, this danger can be reduced to a
large degree through appropriate use of data partition-
ing and sampling schemes.
In general, three independent sets of samples are
needed for the development and evaluation of a classiﬁ-
cation system [134]. One set is called the training set and
used for training a classiﬁer. During or after classiﬁer
training, the classiﬁer should be pruned and adjusted
to avoid possible overtraining using another, indepen-
dent sample set, which is referred as the validation set.As described in the previous section on classiﬁer train-
ing, the error on the validation set tends to increase after
a certain time point while the error on the training set
keeps decreasing as the training process continues. The
time point at which the error on the validation set starts
to increase is the point when training should conclude.
The validation set is used to ﬁnd the stopping point of
training. After the classiﬁer is developed using the train-
ing and validation sets, it must be evaluated with respect
to the general population. The test set is used to estimate
the true error of the classiﬁer on the general population.
It is also important to recognize that a mass spectrome-
try analysis is actually composed of a series of chemical/
biochemical processes. Thus, within a data set samples
must be randomized in each analytical step so as to
avoid any possible bias due to batch processing because
such bias could produce systematic patterns that inter-
fere the ‘‘true’’ patterns originating from the pathologi-
cal changes in the samples.
Typically, the same data (training set) are used in the
procedures of preprocessing, feature extraction, feature
selection, and classiﬁer training. The use of separate sets
for choosing algorithms and setting their parameters in
each of these stages would provide greater protection
against overtraining. Unfortunately, this is seldom plau-
sible given realistic sample sizes. In fact, in most studies
of cancer classiﬁcation using mass spectra, the number
of available samples is not even large enough to produce
three independent sample sets. Even when three non-
overlapping sets are used, they are typically partitioned
from a single set and as such as are not truly ‘‘indepen-
dent’’ sets. We are aware of very few studies of cancer
classiﬁcation using mass spectra of human blood sam-
ples that have employed a truly independent test set
(e.g., test set was generated on a diﬀerent day than the
training set) [43].
The small number of cases necessitates the use of
sampling techniques such as k-fold cross-validation,
bootstrap sampling [152–154], or random partitioning
(Fig. 6) to estimate the generalization ability of the clas-
siﬁer. Sampling techniques are used to obtain estimates
of classiﬁer performance by judicious reuse of data.
However, it should be noted that no sampling technique
can perfectly address the question of how systematic and
realistic variations in the data source (e.g., variations in
a single mass spectrometer over time or between two
mass spectrometers) will impact the general classiﬁer
performance. A classiﬁcation system must ultimately
be evaluated using a large, independent data set.
In k-fold cross-validation, the data are split into k
non-overlapping subsets or ‘‘folds’’ such that each sam-
ple is present in a single fold [152]. The classiﬁer is
trained on k  1 of the folds and tested on the remaining
fold. This process is repeated such that each fold is with-
held once. Usually, the average of the evaluation results
(e.g., accuracies) across the folds is taken as the estimate
Fig. 6. The left panel illustrates k-fold cross-validation and the right panel illustrates bootstrap sampling. In k-fold cross-validation, the data are split
into k non-overlapping subsets or ‘‘folds’’ such that each sample is present in a single fold. The classiﬁer is trained on k  1 of the folds and tested on
the remaining fold. This process is repeated such that each fold is withheld once. Usually, the average of evaluation results (e.g., accuracies) across the
folds is taken as the estimate of the overall system performance. By comparison, a bootstrap set is created by random sampling of N cases with
replacement from the original set of N cases. A classiﬁer is trained on one such bootstrap set and tested on another. The process is repeated many
times and the average of the evaluation results across the bootstrap sets is taken as the estimate of the system performance.
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62,64,73,125,49,50,66,56,52,80,42,71]. When k is equal
to the number of samples, this procedure is called
leave-one-out cross-validation. In leave-one-out cross-
validation, every sample is tested exactly one time and
the overall system performance is estimated by simply
gathering the individual sample validation results as if
these test results came from a single classiﬁer [32,58,
61,38,63,65,66,40,70,71,43]. Note that the actual num-
ber of classiﬁers trained is equal to the value of k in
the cross-validation.
It is important to remember that the performance esti-
mates obtained by k-fold cross-validation are aﬀected by
the size of the training set and the number of folds. An
estimator is evaluated in terms of its bias, the extent to
which the average system performance estimate is close
to the true system performance in the population, and
its variance, the extent to which the estimates spread
around the average system performance estimate [155].
The estimate of the true system performance is more
biased as the size of the training set decreases and has
higher variance as the size of the testing set decreases
[156,157]. Therefore, a cross-validation using a larger va-
lue for k will result in an estimate with less bias, but high-
er variance relative to a cross-validation using a smaller
value for k. Several excellent texts are available that dis-
cuss the trade-oﬀs between bias and variance in classiﬁer
evaluation [155,126,156,157].
The bootstrap sampling is another technique to esti-
mate the true system performance with a limited number
of samples [152,153]. A bootstrap set is created by ran-
dom sampling of N cases with replacement from the ori-
ginal set of N cases. A classiﬁer is trained on one such
bootstrap set and tested on another. The process is
repeated many times and the average of the evaluationresults across the bootstrap sets is taken as the estimate
of the system performance [34,42]. Note that each
bootstrap set created for training results in a separate
classiﬁer. One study [42] employed 0.632+ bootstrap
sampling, a modiﬁed version of bootstrap sampling,
which can alleviate the bias in estimating the true system
performance [157].
Random partitioning can be regarded as single or
multiple 2-fold cross-validation. It is also similar to
bootstrap sampling except that sampling is performed
without replacement and less than N of N cases are se-
lected. The training set is generated by randomly sam-
pling a certain portion of data and the remaining
samples of data are used as the test set [44,74,34,36,47,
64,48,39,49,50,41,51,56,70,53].
Commonly, cross-validation, bootstrap sampling,
and random partitioning are used to estimate the system
performance during the classiﬁer training stage. How-
ever, some studies have applied random partitioning to
derive reliably discriminant features during feature
selection [74,77,46,55] based on the ranks of discrimi-
nant features that are earned on each sampled training
data set. The features with consistently high ranks are
selected for use. However, in practice, it is often impos-
sible or very diﬃcult for the entire design process to be
performed in a cross-validation manner. As a conse-
quence, several previous studies seem to have used the
full data set prior to cross-validation for feature selec-
tion [77,47,63,73,66,69,42]. As was the case for estimat-
ing system performance, sampling techniques cannot
overcome limitations that are inherent to the data set
from which the samples are drawn. If the data set does
not represent the underlying probability distribution of
the population of interest, then even the most sophisti-
cated feature selection based on sampling techniques
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tures [148].
It is critical that the system evaluation be based on
criteria that are clinically relevant and be quantitative
with clearly deﬁned standards of interpretation. While
classiﬁers typically attempt to optimize an evaluation
function as part of the training process, it is important
recognize that in general that function is not the most
clinically relevant measure. For example, the mean-
square error measure weights the two possible kinds of
error equally while in most medical diagnostic tasks
the costs, monetary and otherwise, of false-positives
and false-negatives are not equal.
Accuracy, the fraction of the samples that the system
correctly classiﬁes, has been used in many mass spec-
trometry studies that employ a binary decision approach
[58,82,60,36,136,61,37,38,47,62–64,125,65,81,40,69,52,42,
70,71]. However, there is a signiﬁcant drawback to the
accuracy metric in that it is dependent on the prevalence
of disease in the data set. For example, if there are only
20 disease cases for every 80 normal cases, a system
could achieve 80% accuracy by simply reporting all cases
as normal. Thus, if the prevalence is not 50%, the system
accuracy cannot be interpreted in isolation. The most
clinically relevant measures for screening and diagnostic
tests are sensitivity and speciﬁcity, regardless of whether
the test involves a computational aid. Many studies of
mass spectrometry for cancer classiﬁcation have used
these measures [44,32,54,74,45,33,97,75,77,36,46,55,38,
47,63,39,73,125, 49,50,66,41,51,56,133,69,80,53,43].
Receiver operating characteristic (ROC) analysis can
be used for diagnostic systems that provide a range of
outputs rather than a binary classiﬁcation. An ROC
curve is a plot of the sensitivity vs. (1-speciﬁcity), or
equivalently the true positive fraction vs. the false posi-
tive fraction, computed from the application of a series
of thresholds to the system output (Fig. 7). The advan-
tage of ROC analysis is that it explicitly shows the trade-
oﬀs in sensitivity and speciﬁcity that could be achievedFig. 7. Receiver operating characteristic (ROC) analysis can be used
to evaluate diagnostic systems that provide a range of outputs rather
than a binary classiﬁcation. An ROC curve is a plot of the sensitivity
vs. (1-speciﬁcity), or equivalently the true positive fraction vs. the false
positive fraction, computed from the application of a series of
thresholds to the system output. A measure of the concaveness of
ROC curves is the area under the curve (AUC).with the same classiﬁcation system. In essence, the
choice of the decision threshold is delayed until a later
time when more knowledge may be available on the
costs associated with each type of error.
In general, ROC curves are concave and better sys-
tem performance corresponds to more concave curves.
A measure of the concaveness of ROC curves is the area
under the curve (AUC). Hence, the AUC has been used
as a measure of system performance in many studies
[74,77,36,136,55,38,63,125,66,80].
Evaluation metrics (e.g., ROC AUC) are calculated
based on a given data samples, yet it is the performance
on the general population that matters. Therefore, there
is a need to estimate the reliability of the system. For
this purpose, some studies have randomly permuted
the class labels of samples and compared the perfor-
mance to that from using the actual class labels
[61,64,69,52]. As the diﬀerence between two becomes
larger, the performance evaluation from the actual sam-
ples is taken as a more reliable indicator of how the sys-
tem would perform on the general population.
When sampling techniques are used, care must be ta-
ken not to mistakenly tune classiﬁer performance results
on the ‘‘testing’’ portions. For example, several studies
appear to have determined the threshold for calculating
the sensitivity and speciﬁcity based on the ‘‘testing’’ por-
tion of the data rather than the ‘‘training’’ portion
[74,77,36,55,38,47,63,73,66]. These practices can par-
tially undermine the protection against overtraining pro-
vided by those sample techniques.
The use of appropriate data sampling methods and
relevant evaluation metrics can provide substantial reas-
surance that laboratory studies will contribute towards
the goal of accurate and reliable clinical decision sup-
port systems. Of course, laboratory studies must be fol-
lowed by rigorous clinical testing. For example, studies
of the way that the healthcare team does, or does not,
incorporate the recommendations made by a system
based on the mass spectrometry data is beyond the
scope of this review. Ultimately, long-term, large clinical
trials are required to establish the eﬃcacy of any screen-
ing test to the level of a decrease in cause-speciﬁc
mortality.5. Summary
An ideal screening method should be accurate, reli-
able, rapid, inexpensive, and minimally invasive. Proteo-
mic proﬁling of blood samples using mass spectrometry
has recently been proposed as a method that has the po-
tential to meet these goals. However, there are key diﬃ-
culties that must be addressed before clinical diagnostic
tools can be developed based on this technology. Chief
among these is to overcome the restrictions on reliability
that have plagued early studies. To achieve accurate
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the classiﬁer can also be generalized such that new,
but similar, data can be accurately classiﬁed. A system
for discriminating proteomic patterns of samples from
healthy and ill people must be robust to the variability
that will exist across people, mass spectrometers, sample
collection protocols, days, etc.
This article reviews the literature on developing clin-
ical decision support systems for cancer screening from
proteomic patterns obtained by mass spectrometry of
blood samples from a machine learning perspective.
Prior studies are presented in an explicit machine learn-
ing framework consisting of ﬁve stages: preprocessing,
feature extraction, feature selection, classiﬁer training,
and evaluation. The purpose of preprocessing is to re-
duce the inﬂuence of aspects of the data that are not ex-
pected to aid in the goal of discrimination between
disease and healthy patterns and instead may make that
classiﬁcation task more diﬃcult. In feature extraction,
the aim is to reduce the dimensionality of the data and
increase the interpretability by deﬁning numerical sum-
mary measures, often called ‘‘features.’’ Following fea-
ture extraction, it is necessary to perform a feature
selection step in which a subset of features that best en-
able discrimination between the two groups is identiﬁed.
Given a set of spectra summarized by informative fea-
tures and with corresponding truth (health status), a
variety of classiﬁcation algorithms can be trained. Final-
ly, care must be taken in the choice of experimental
design (e.g., data sampling) and evaluation criteria to as-
sess both accuracy and reliability (generalization).
It is apparent that the components of the framework
that are most speciﬁc to the data type, mass spectra of
blood samples, are preprocessing, feature extraction,
and feature selection. We hypothesize that improve-
ments in these components will yield the greatest in-
crease in system reliability and that the approaches
most likely to achieve those improvements will be based
on explicit models of the data generation. While the
objective of developing a clinical decision support sys-
tem for cancer screening from proteomic patterns is ulti-
mately data driven, we argue that this goal may not be
achievable with reasonable sample sizes unless we use
knowledge of the related biology, chemistry, and engi-
neering to constrain the design process.Acknowledgments
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